Key facts

Invented name
Olumiant
Active Substance
Baricitinib
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0004/2022
PIP number
EMEA-001220-PIP01-11-M06
Pharmaceutical form(s)
  • Oral suspension
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
Route(s) of administration
Oral use
Contact for public enquiries

Eli Lilly & Company Limited

Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date

Decision

P/0004/2022 : EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for baricitinib (Olumiant), (EMEA-001220-PIP01-11-M06)

How useful do you find this page?